Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transnasal Fluoroscopic-Guided Eustachian Tube Obliteration With a Liquid Embolic Agent for a Recurrent Cerebrospinal Fluid Leak After Translabyrinthine Schwannoma Surgery: A Case Series.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2025
Same author

[Gliomatosis cerebri as cause of neuropsychiatric symptoms].

Duodecim; laaketieteellinen aikakauskirja·2014
Same author

[Tongue abscess].

Duodecim; laaketieteellinen aikakauskirja·2014
Same author

[Myelitis following vaccination against tick-borne encephalitis].

Duodecim; laaketieteellinen aikakauskirja·2012
Same author

[Fatal tick-borne encephalitis].

Duodecim; laaketieteellinen aikakauskirja·2011
Same author

Advanced magnetic resonance imaging techniques in the diagnostics of Alzheimer's disease: how much imaging is enough?

Acta radiologica (Stockholm, Sweden : 1987)·2011

Related Experiment Video

Updated: Apr 6, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

5.1K

[Progressive multifocal encephalopathy in a LED patient].

Tapani Tikkakoski, Sinikka Ingo, Lillemor Julin

    Duodecim; Laaketieteellinen Aikakauskirja
    |August 5, 2015
    PubMed
    Summary

    Progressive multifocal encephalopathy (PML) is a rare brain disease caused by JC virus reactivation during immunosuppression. This report details the first Finnish case of PML linked to rituximab treatment in a Lymphomatoid Eosinophilic Dermatosis patient.

    More Related Videos

    Author Spotlight: Unveiling Cellular Functions and Potential Clinical Implications of Leptomeningeal Lymphatic Endothelial Cells
    06:44

    Author Spotlight: Unveiling Cellular Functions and Potential Clinical Implications of Leptomeningeal Lymphatic Endothelial Cells

    Published on: September 8, 2023

    2.7K
    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
    06:25

    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

    Published on: March 29, 2024

    1.7K

    Related Experiment Videos

    Last Updated: Apr 6, 2026

    A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
    04:55

    A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

    Published on: May 11, 2022

    5.1K
    Author Spotlight: Unveiling Cellular Functions and Potential Clinical Implications of Leptomeningeal Lymphatic Endothelial Cells
    06:44

    Author Spotlight: Unveiling Cellular Functions and Potential Clinical Implications of Leptomeningeal Lymphatic Endothelial Cells

    Published on: September 8, 2023

    2.7K
    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
    06:25

    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

    Published on: March 29, 2024

    1.7K

    Area of Science:

    • Neurology
    • Immunology
    • Virology

    Background:

    • Progressive multifocal encephalopathy (PML) is a rare, opportunistic demyelinating disease of the central nervous system.
    • PML is caused by the reactivation of the JC virus (JCV) in immunocompromised individuals.
    • The epidemiology of PML has shifted, with an increased incidence associated with specific immunosuppressive therapies, including monoclonal antibodies.

    Observation:

    • This study reports the first documented case of PML in Finland.
    • The patient had Lymphomatoid Eosinophilic Dermatosis (LED) and was undergoing treatment with rituximab, a monoclonal antibody.
    • The case highlights a potential link between rituximab therapy and PML development in LED patients.

    Findings:

    • The case confirms rituximab as a potential risk factor for PML development.
    • This represents a novel geographical and etiological association for PML.
    • The findings underscore the importance of monitoring for PML in patients receiving rituximab, particularly those with underlying conditions like LED.

    Implications:

    • Clinicians should be vigilant for PML symptoms in patients treated with rituximab, especially those with conditions causing immunosuppression.
    • This case may prompt further research into the specific risks of rituximab-associated PML in different patient populations.
    • Enhanced surveillance and diagnostic protocols may be necessary for early detection and management of PML in at-risk individuals.